Targeting ALDH3B2 for Drug Development (G222)

Target Name: ALDH3B2

NCBI ID: G222

ALDH3B2

Targeting ALDH3B2 for Drug Development

Aldehyde dehydrogenase family 3 member B2 (ALDH3B2) is a enzyme that plays a crucial role in the metabolism of various molecules, including toxins and environmental pollutants. Mutations in the ALDH3B2 gene have been linked to a range of human diseases, including neurodegenerative disorders, reproductive organ problems, and systemic diseases. As a result, targeting ALDH3B2 has become an attractive target for drug development and research.

Drug Targets and ALDH3B2

ALDH3B2 is a key enzyme in the metabolic pathway of the xenobiotics, which are a common class of environmental toxins that can be found in various forms, including pesticides, polychlorinated biphenyls (PCBs), and polycyclic aromatic hydrocarbons (PAHs). These toxins can be harmful to human health and have been linked to a range of diseases, including cancer, neurodegenerative disorders, and reproductive problems.

Research has shown that ALDH3B2 plays a key role in the detoxification of these xenobiotics. By participating in the xenobiotic metabolism, ALDH3B2 helps to reduce their toxicity and protects against their harmful effects on the body. Therefore, targeting ALDH3B2 has the potential to be a useful drug target for the development of new treatments for a range of diseases.

Biomarkers and ALDH3B2

ALDH3B2 is also a potential biomarker for a range of diseases. Since ALDH3B2 is involved in the detoxification of xenobiotics, changes in its expression levels or activity can be an indication of the presence of these toxins in the body. For example, increased expression of ALDH3B2 has been linked to the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Similarly, decreased ALDH3B2 activity has been associated with the development of reproductive problems, such as infertility and decreased fertility.

Targeting ALDH3B2

Targeting ALDH3B2 is an attractive strategy for the development of new drugs and therapies for a range of diseases. One approach is to use small molecules, such as drugs that bind to ALDH3B2 and inhibit its activity. This can be a useful way to target the enzyme and reduce its production of toxic metabolites.

Another approach to targeting ALDH3B2 is to use antibodies that recognize and label the enzyme in the body. This can help to track the distribution and activity of the enzyme, and can be useful for studying its role in various diseases.

Conclusion

In conclusion, ALDH3B2 is an enzyme that plays a crucial role in the metabolism of xenobiotics and has been linked to a range of human diseases. As a result, targeting ALDH3B2 has become an attractive target for drug development and research. By using small molecules or antibodies, researchers have the potential to develop new treatments for a range of diseases. Further research is needed to fully understand the role of ALDH3B2 in human health and to develop effective treatments.

Protein Name: Aldehyde Dehydrogenase 3 Family Member B2

Functions: Oxidizes medium and long chain aldehydes into non-toxic fatty acids

The "ALDH3B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALDH3B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets